840 related articles for article (PubMed ID: 32539853)
1. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
[TBL] [Abstract][Full Text] [Related]
2. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial.
Midgard H; Malme KB; Pihl CM; Berg-Pedersen RM; Tanum L; Klundby I; Haug A; Tveter I; Bjørnestad R; Olsen IC; Finbråten AK; Dalgard O
Clin Infect Dis; 2024 Mar; 78(3):582-590. PubMed ID: 37992203
[TBL] [Abstract][Full Text] [Related]
4. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Leiva RA; Ohldieck C; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
PLoS Med; 2021 Jun; 18(6):e1003653. PubMed ID: 34061883
[TBL] [Abstract][Full Text] [Related]
5. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
[TBL] [Abstract][Full Text] [Related]
6. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D;
BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.
Litwin AH; Jost J; Wagner K; Heo M; Karasz A; Feinberg J; Kim AY; Lum PJ; Mehta SH; Taylor LE; Tsui JI; Pericot-Valverde I; Page K;
Contemp Clin Trials; 2019 Dec; 87():105859. PubMed ID: 31669450
[TBL] [Abstract][Full Text] [Related]
8. Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial.
Malme KB; Stene-Johansen K; Klundby I; Backe Ø; Foshaug T; Greve MH; Pihl CM; Finbråten AK; Dalgard O; Midgard H
Viruses; 2024 May; 16(6):. PubMed ID: 38932151
[TBL] [Abstract][Full Text] [Related]
9. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
11. Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.
Pericot-Valverde I; Heo M; Akiyama MJ; Norton BL; Agyemang L; Niu J; Litwin AH
BMC Infect Dis; 2020 Dec; 20(1):928. PubMed ID: 33276738
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
[TBL] [Abstract][Full Text] [Related]
13. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
Litwin AH; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Heo M; Arnsten J; Meissner P; Karasz A; Mckee MD; Ward JW; Johnson N; Pericot-Valverde I; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Roche J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Page K;
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1112-1127. PubMed ID: 36370741
[TBL] [Abstract][Full Text] [Related]
14. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
[TBL] [Abstract][Full Text] [Related]
17. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
19.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs.
Wade AJ; Doyle JS; Gane E; Stedman C; Draper B; Iser D; Roberts SK; Kemp W; Petrie D; Scott N; Higgs P; Agius PA; Roney J; Stothers L; Thompson AJ; Hellard ME
Clin Infect Dis; 2020 Apr; 70(9):1900-1906. PubMed ID: 31233117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
